End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
715 IDR | 0.00% | -0.69% | +36.19% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company is one of the best yield companies with high dividend expectations.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+36.19% | 1.34B | - | ||
+42.38% | 6.26B | B- | ||
-15.86% | 4.49B | C+ | ||
+6.36% | 3.29B | C | ||
-11.28% | 3.12B | B- | ||
-3.23% | 2.5B | - | D+ | |
+45.24% | 1.94B | - | ||
-7.89% | 1.68B | - | - | |
-0.98% | 1.63B | - | - | |
-11.32% | 1.56B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SIDO Stock
- Ratings PT Industri Jamu dan Farmasi Sido Muncul Tbk